Dalal Street Blogs provides information for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
CAUTION: Dalal Street Blogs publishes market news and educational content only. We do not promote, recommend or endorse any stock, and nothing here is a solicitation to buy or sell securities. Please consult a SEBI-registered adviser before investing.
Market News

Sun Pharma Q2 Results (Oct 30 2026): Profit Falls 36% on One-Offs, Revenue Up 11.9%

3757
By Dalal Street Blogs EditorialUpdated 3 min read

Sun Pharma Q2 results, announced on Friday, October 30, look worse on the headline than they really are. Consolidated net profit fell 36% year-on-year to ₹1,988.5 crore for the September 2026 quarter, Business Standard reported. Strip out two one-time charges, though, and profit actually edged up. Revenue from operations rose 11.9% to ₹16,198.7 crore.

In this article
  1. Sun Pharma Q2 results: what dragged profit down
  2. India did the heavy lifting
  3. The US is still the soft spot
  4. Organon deal, R&D and guidance
  5. What it means for investors

Sun Pharma Q2 results: what dragged profit down

The damage came from exceptional items worth ₹1,268.8 crore. Of that, ₹922.7 crore went towards settling an antitrust case in the US, and ₹346.2 crore was spent on its proposed acquisition of Organon, according to Business Standard. Neither is a cost of running the business day to day.

Excluding those charges, adjusted net profit was ₹3,162 crore, up 1.4% from a year ago. That’s the cleaner number, and it tells us the core business held steady rather than grew fast.

Operating performance was a little softer. EBITDA (earnings before interest, tax, depreciation and amortisation) rose 4.8% to ₹4,744 crore, but the EBITDA margin slipped to 29.3% from 31.3% a year earlier, The Economic Times reported. The company said the year-ago quarter had the benefit of generic lenalidomide sales, a product now losing ground in the US. Gross margin improved to 80.8%, while the effective tax rate went up to 28.3% from 24.7%.

India did the heavy lifting

The domestic business was the standout. India formulation sales grew 17.3% to ₹5,552.3 crore and made up 34.5% of consolidated sales. Business Standard, citing Pharmarack’s moving annual total data for September, said Sun’s market share in India rose to 8.6% from 8.3%. The company launched 14 products in the quarter.

Emerging markets formulation sales grew 7.6% to $350 million, and rest-of-world sales rose 3.1% to $241 million. The global innovative medicines business grew 6.9% to $356 million.

The US is still the soft spot

US formulation sales fell 8.2% to $455 million, about 27% of total sales, mainly because of the lenalidomide erosion. There was some relief sequentially: sales grew 6.5% over the June quarter, helped by five generic launches. Management also admitted on the earnings call that Ilumya sales in the US had slowed, partly due to execution, and said it has stepped in to fix that.

On the pipeline, Sun got US approval for Ilumya in adults with active psoriatic arthritis, and Unloxcyt picked up a preferred recommendation from the National Comprehensive Cancer Network. We covered that second development in our earlier note on Sun Pharma’s Unloxcyt NCCN listing.

Organon deal, R&D and guidance

The Organon acquisition is on track to close in the fourth quarter of FY27, with approvals in hand for most regions, Business Standard said. Expect more deal-related costs to show up until then; the company said so itself.

R&D spending was ₹778.4 crore, or 4.8% of sales. Chairman Dilip Shanghvi said that’s below what the company intends to spend and the second half should catch up. Despite double-digit revenue growth in the first half, management stuck with its full-year forecast of high single-digit revenue growth.

For the first half of FY27, consolidated revenue rose 11% to ₹31,284 crore and adjusted net profit grew 2.2% to ₹6,252 crore, per ET.

What it means for investors

The market seemed to read past the headline. The results came out during trading hours, and Sun Pharma shares closed 0.8% higher at ₹1,778.25 on the BSE. Our take: the profit fall is mostly accounting noise from one-offs, India growth is strong, and the US business plus pending Organon costs are what to track next quarter. Higher R&D in the second half could also squeeze margins a bit. If you want to read results like these yourself, our guide on how to analyse quarterly results of a company is a good place to start.

Disclaimer: This article is for information and education only and is not investment advice. Please do your own research or consult a SEBI-registered adviser before making any investment decision.

Leave a Reply

Join the conversation

Commenting is open to registered readers. Sign up with just your email — no password needed, and it takes under a minute.

Sign up to comment Log in